About this episode

This episode discusses a study comparing semaglutide and canagliflozin in the treatment of Type 2 Diabetes.

In this episode of Hormone Insight, we delve into a major study published in The Lancet Diabetes and Endocrinology that compared the effects of semaglutide and canagliflozin as add-ons to metformin in diabetes treatment. For more: Semaglutide vs Canagliflozin for Type 2 Diabetes To read the original paper

More episodes of Hormone Insight

• HORMONE INSIGHT -- THE WEEK IN DIABETES & ENDOCRINOLOGY -- Episode 004 | April 24, 2026 · April 24, 2026 · 14 min
• The Week in Diabetes and Endocrinology April 17, 2026 · April 22, 2026 · 18 min
• Episode 002: LDL Under 55 Wins Big, Medicare Covers GLP-1, and Second Weekly Insulin Emerges -- The Week in Diabetes & Endocrinology (April 10, 2026) · April 9, 2026 · 17 min
• The Week in Diabetes and Endocrinology -- April 3, 2026 · April 5, 2026 · 24 min
• Early Onset Type 2 Diabetes and Tirzepatide (SURPASS Post Hoc Analysis) · June 14, 2025 · 1 min
• Exploring Semaglutide: Therapy for Obesity and Heart Failure · January 4, 2025 · 1 min

Explore listener stats, chart rankings, contacts and more on the Hormone Insight podcast page.